LTRN
Lantern Pharma Inc
0.64$
-3.2%
vs. previous close
Closing price · As of: Nov 2, 2026
Filings
Filings
Listed US companies must report material events to the Securities and Exchange Commission. This page lists the filings of Lantern Pharma Inc (LTRN) with date, type and a link to the original document.
| Date | Type | Filing | Original |
|---|---|---|---|
| 10/01/2026 | Current report (8-K) | Lantern Pharma Inc. (LTRN): Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | View report ↗ |
| 09/30/2026 | Current report (8-K) | Lantern Pharma Inc. (LTRN): Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Statements and Exhibits | View report ↗ |
| 09/30/2026 | Capital measure | Form 424B5 filed with the SEC | View document ↗ |
| 09/24/2026 | Current report (8-K) | Lantern Pharma Inc. (LTRN): Regulation FD Disclosure; Financial Statements and Exhibits | View report ↗ |
| 09/23/2026 | Current report (8-K) | Lantern Pharma Inc. (LTRN): Regulation FD Disclosure; Financial Statements and Exhibits | View report ↗ |
| 08/14/2026 | Current report (8-K) | Lantern Pharma Inc. (LTRN): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits | View report ↗ |
| 08/04/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document ↗ |
| 08/03/2026 | Current report (8-K) | Lantern Pharma Inc. (LTRN): Regulation FD Disclosure; Financial Statements and Exhibits | View report ↗ |
Showing the 100 most recent filings of the selected type.
Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Filings: SEC EDGAR
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.